Silo Pharma, Inc.
- Jurisdiction
United States - ISIN
US82711P2011 (SILO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. Read full profile
Stock price
Fundamentals
- Net revenue
€62.23K - Gross margin
91.9% - EBIT
-€4.46M - EBIT margin
-7,165.0% - Net income
-€4.22M - Net margin
-6,789.2%
Statement period: - (published )
Dividends
No dividend payouts